US4021492A
(en)
*
|
1975-03-24 |
1977-05-03 |
Sandoz, Inc. |
Dibromination process
|
SE414305B
(sv)
*
|
1976-08-25 |
1980-07-21 |
Astra Laekemedel Ab |
Analogiforfarande for framstellning av eventuellt substituerade 2-amino-6-fenyl-5,5dimetyl 3-hexanon med antidepressiv aktivitet
|
US4318791A
(en)
*
|
1977-12-22 |
1982-03-09 |
Ciba-Geigy Corporation |
Use of aromatic-aliphatic ketones as photo sensitizers
|
FR2430933A1
(fr)
*
|
1978-07-13 |
1980-02-08 |
Synthelabo |
Derives de propiophenone et leur application en therapeutique
|
US4347257A
(en)
*
|
1979-10-09 |
1982-08-31 |
Burroughs Wellcome Co. |
Prolactin suppression in mammals
|
FR2486074A1
(fr)
*
|
1979-12-14 |
1982-01-08 |
Lafon Labor |
Derives de fluorophenacyl-amine, leur procede de preparation et leur application en therapeutique
|
EP0038071B1
(de)
*
|
1980-04-14 |
1984-11-14 |
The Wellcome Foundation Limited |
Radioaktiv markierte und unmarkierte Butylaminopropiophenon-Derivate, ihre Herstellung, aus den unmarkierten Derivaten erzeugte Immunogene und ein Verfahren zur Herstellung der Antisera, durch Immunogen hergestellte Antisera und Verfahren zur Herstellung der Antisera, ein Radioimmunoassayverfahren und eine Reagentiengarnitur zum Gebrauch bei dieser Methode
|
ATE8987T1
(de)
*
|
1981-03-23 |
1984-09-15 |
Laboratoire L. Lafon Societe Anonyme Dite: |
Fluorphenacyl-amin-derivate und ihre therapeutische verwendung.
|
JPS57169450A
(en)
*
|
1981-04-13 |
1982-10-19 |
Lafon Labor |
Fluorophenacyl-amine derivative and application to remedy
|
US4393078A
(en)
*
|
1982-03-15 |
1983-07-12 |
Burroughs Wellcome Co. |
Bupropion and ethanol
|
USRE33994E
(en)
*
|
1983-08-16 |
1992-07-14 |
Burroughs Wellcome Co. |
Pharmaceutical delivery system
|
US4507323A
(en)
*
|
1984-07-25 |
1985-03-26 |
Burroughs Wellcome Co. |
Treatment of psychosexual dysfunctions
|
FR2569185B1
(fr)
*
|
1984-08-20 |
1986-09-05 |
Lafon Labor |
Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique
|
US5236922A
(en)
*
|
1984-08-20 |
1993-08-17 |
Laboratoire L. Lafon |
Method for treating depression using 1-(aminophenyl)-2-aminopropanone derivatives
|
FR2569184A1
(fr)
*
|
1984-08-20 |
1986-02-21 |
Lafon Labor |
Derives de 1-(aminophenyl) therapeutique et leur procede de preparation
|
GB9217295D0
(en)
*
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
US5541231A
(en)
*
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
GB9315856D0
(en)
*
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5358970A
(en)
*
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5753712A
(en)
*
|
1994-02-18 |
1998-05-19 |
Pinsker; Walter |
Treatment of migraine headaches and formulations
|
WO1995022324A1
(en)
*
|
1994-02-18 |
1995-08-24 |
Walter Pinsker |
Treatment of migraine headaches and formulations
|
US6652882B1
(en)
*
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
WO1999038503A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmacological uses of optically pure (+)-bupropion
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
US6150420A
(en)
*
|
1998-06-01 |
2000-11-21 |
Theramax, Inc. |
Method for enhanced brain delivery of bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
EP3173082A1
(de)
*
|
2002-05-17 |
2017-05-31 |
Duke University |
Verfahren zur behandlung von adipositas
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
EP1523334A2
(de)
*
|
2002-07-18 |
2005-04-20 |
Cytos Biotechnology AG |
Hapten-träger-konjugate und ihre verwendung
|
AU2002337634A1
(en)
*
|
2002-09-10 |
2004-04-30 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Process for the preparation of bupropion hydrochloride
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
ITMI20030762A1
(it)
*
|
2003-04-11 |
2004-10-12 |
Erregierre Spa |
Processo di cristallizzazione del bupropione cloridrato.
|
SI2316456T1
(sl)
*
|
2003-04-29 |
2017-10-30 |
Orexigen Therapeutics, Inc. |
Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
|
EP2112920B1
(de)
|
2003-06-26 |
2018-07-25 |
Intellipharmaceutics Corp. |
Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
CA2547283C
(en)
*
|
2003-11-26 |
2010-11-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
WO2005060968A1
(en)
|
2003-12-11 |
2005-07-07 |
Sepracor Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
AU2005206139B2
(en)
|
2004-01-13 |
2009-02-26 |
Duke University |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
WO2005107806A1
(en)
*
|
2004-04-21 |
2005-11-17 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
EP1896002A4
(de)
*
|
2005-06-27 |
2009-11-25 |
Biovail Lab Int Srl |
Bupropionsalzformulierungen mit modifizierter freisetzung
|
AU2006269231A1
(en)
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
EP2258357A3
(de)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenese mit Acetylcholinesterasehemmer
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
EP1945198A4
(de)
*
|
2005-10-14 |
2009-08-26 |
Lundbeck & Co As H |
Stabile pharmazeutische formulierungen mit escitalopram und bupropion
|
JP2009511606A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
CN101370488B
(zh)
|
2005-11-22 |
2012-07-18 |
奥雷西根治疗公司 |
增加胰岛素敏感性的组合物
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
CA2635261A1
(en)
*
|
2006-01-03 |
2007-07-12 |
Algebra, Inc. |
Therapeutic amine-arylsulfonamide conjugate compounds
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
JP5457830B2
(ja)
*
|
2006-04-03 |
2014-04-02 |
オディディ,イサ |
オルガノゾル被膜を含む制御放出送達デバイス
|
WO2007117581A2
(en)
*
|
2006-04-06 |
2007-10-18 |
Collegium Pharmaceutical, Inc. |
Stabilized transdermal bupropion preparations
|
EP2021000A2
(de)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenese mittels angiotensin-modulation
|
EP2026813A2
(de)
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5-ht-rezeptor-vermittelte neurogenese
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
JP2010502722A
(ja)
|
2006-09-08 |
2010-01-28 |
ブレインセルス,インコーポレイティド |
4−アシルアミノピリジン誘導体を含む組み合わせ
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
KR101735466B1
(ko)
|
2006-11-09 |
2017-05-15 |
오렉시젠 세러퓨틱스 인크. |
신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
|
KR20090090316A
(ko)
|
2006-11-09 |
2009-08-25 |
오렉시젠 세러퓨틱스 인크. |
체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
|
CA2691208A1
(en)
*
|
2007-06-18 |
2008-12-24 |
The General Hospital Corporation |
Combination therapy for depression
|
CN100560563C
(zh)
*
|
2007-07-06 |
2009-11-18 |
浙江普洛医药科技有限公司 |
盐酸安非他酮的合成方法
|
US20090076161A1
(en)
*
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bupropion
|
US20090148541A1
(en)
*
|
2007-10-16 |
2009-06-11 |
Duke University |
Compositions and methods for the treatment of seborrhea
|
US9339500B2
(en)
*
|
2008-03-04 |
2016-05-17 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
JP2011521973A
(ja)
|
2008-05-30 |
2011-07-28 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
内臓脂肪の状態を処置するための方法
|
WO2010004386A2
(en)
*
|
2008-06-16 |
2010-01-14 |
Glenmark Generics Limited |
Amorphous bupropion hydrobromide and preparation thereof
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
CA2758774C
(en)
|
2009-04-15 |
2015-02-03 |
Research Triangle Institute |
Monoamine reuptake inhibitors
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
BR112012016783A2
(pt)
|
2010-01-11 |
2015-09-01 |
Orexigen Therapeutics Inc |
"usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
|
AU2013271622B2
(en)
|
2012-06-06 |
2018-03-01 |
Nalpropion Pharmaceuticals Llc |
Methods of treating overweight and obesity
|
US10813924B2
(en)
|
2018-03-20 |
2020-10-27 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for treating nicotine addiction
|
US11382874B2
(en)
|
2013-11-05 |
2022-07-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9198905B2
(en)
|
2013-11-05 |
2015-12-01 |
Antecip Bioventures Ii Llc |
Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
|
US9408815B2
(en)
|
2013-11-05 |
2016-08-09 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11426370B2
(en)
|
2013-11-05 |
2022-08-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9457025B2
(en)
|
2013-11-05 |
2016-10-04 |
Antecip Bioventures Ii Llc |
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
|
US11497721B2
(en)
|
2013-11-05 |
2022-11-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11617728B2
(en)
|
2013-11-05 |
2023-04-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11571399B2
(en)
|
2013-11-05 |
2023-02-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11433067B2
(en)
|
2013-11-05 |
2022-09-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11419867B2
(en)
|
2013-11-05 |
2022-08-23 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10966942B2
(en)
|
2019-01-07 |
2021-04-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US20160324807A1
(en)
|
2013-11-05 |
2016-11-10 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9861595B2
(en)
|
2013-11-05 |
2018-01-09 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11058648B2
(en)
|
2013-11-05 |
2021-07-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10080727B2
(en)
|
2013-11-05 |
2018-09-25 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11234946B2
(en)
|
2013-11-05 |
2022-02-01 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10966941B2
(en)
|
2013-11-05 |
2021-04-06 |
Antecip Bioventures Ii Llp |
Bupropion as a modulator of drug activity
|
US10933034B2
(en)
|
2013-11-05 |
2021-03-02 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11096937B2
(en)
|
2013-11-05 |
2021-08-24 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10864209B2
(en)
|
2013-11-05 |
2020-12-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10780064B2
(en)
|
2019-01-07 |
2020-09-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10881657B2
(en)
|
2013-11-05 |
2021-01-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11510918B2
(en)
|
2013-11-05 |
2022-11-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11291665B2
(en)
|
2013-11-05 |
2022-04-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11576909B2
(en)
|
2013-11-05 |
2023-02-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10512643B2
(en)
|
2013-11-05 |
2019-12-24 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11123343B2
(en)
|
2013-11-05 |
2021-09-21 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10772850B2
(en)
|
2013-11-05 |
2020-09-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10688066B2
(en)
|
2018-03-20 |
2020-06-23 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for treating nicotine addiction
|
US11090300B2
(en)
|
2013-11-05 |
2021-08-17 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11065248B2
(en)
|
2013-11-05 |
2021-07-20 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11020389B2
(en)
|
2013-11-05 |
2021-06-01 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11311534B2
(en)
|
2013-11-05 |
2022-04-26 |
Antecip Bio Ventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9707191B2
(en)
|
2013-11-05 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11253491B2
(en)
|
2013-11-05 |
2022-02-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11298351B2
(en)
|
2013-11-05 |
2022-04-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11147808B2
(en)
|
2013-11-05 |
2021-10-19 |
Antecip Bioventures Ii Llc |
Method of decreasing the fluctuation index of dextromethorphan
|
US10980800B2
(en)
|
2013-11-05 |
2021-04-20 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10894046B2
(en)
|
2013-11-05 |
2021-01-19 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11141416B2
(en)
|
2013-11-05 |
2021-10-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11541048B2
(en)
|
2013-11-05 |
2023-01-03 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11298352B2
(en)
|
2013-11-05 |
2022-04-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11185515B2
(en)
|
2013-11-05 |
2021-11-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11357744B2
(en)
|
2013-11-05 |
2022-06-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9474731B1
(en)
|
2013-11-05 |
2016-10-25 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11197839B2
(en)
|
2013-11-05 |
2021-12-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11229640B2
(en)
|
2013-11-05 |
2022-01-25 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US11129826B2
(en)
|
2013-11-05 |
2021-09-28 |
Axsome Therapeutics, Inc. |
Bupropion as a modulator of drug activity
|
US11344544B2
(en)
|
2013-11-05 |
2022-05-31 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US20220233470A1
(en)
|
2013-11-05 |
2022-07-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US20160361305A1
(en)
|
2013-11-05 |
2016-12-15 |
Antecip Bioventures Ii Llc |
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
|
US10898453B2
(en)
|
2013-11-05 |
2021-01-26 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11439636B1
(en)
|
2013-11-05 |
2022-09-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11273133B2
(en)
|
2013-11-05 |
2022-03-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11426401B2
(en)
|
2013-11-05 |
2022-08-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11123344B2
(en)
|
2013-11-05 |
2021-09-21 |
Axsome Therapeutics, Inc. |
Bupropion as a modulator of drug activity
|
US10894047B2
(en)
|
2013-11-05 |
2021-01-19 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11571417B2
(en)
|
2013-11-05 |
2023-02-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11478468B2
(en)
|
2013-11-05 |
2022-10-25 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9457023B1
(en)
|
2013-11-05 |
2016-10-04 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10945973B2
(en)
|
2013-11-05 |
2021-03-16 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9763932B2
(en)
|
2013-11-05 |
2017-09-19 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10799497B2
(en)
|
2013-11-05 |
2020-10-13 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US9700528B2
(en)
|
2013-11-05 |
2017-07-11 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US9968568B2
(en)
|
2013-11-05 |
2018-05-15 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11191739B2
(en)
|
2013-11-05 |
2021-12-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11364233B2
(en)
|
2013-11-05 |
2022-06-21 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10874663B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11007189B2
(en)
|
2013-11-05 |
2021-05-18 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11590124B2
(en)
|
2013-11-05 |
2023-02-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11596627B2
(en)
|
2013-11-05 |
2023-03-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11534414B2
(en)
|
2013-11-05 |
2022-12-27 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10105361B2
(en)
|
2013-11-05 |
2018-10-23 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10874665B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11213521B2
(en)
|
2013-11-05 |
2022-01-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11285146B2
(en)
|
2013-11-05 |
2022-03-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9867819B2
(en)
|
2013-11-05 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10874664B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11617747B2
(en)
|
2013-11-05 |
2023-04-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11517543B2
(en)
|
2013-11-05 |
2022-12-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11253492B2
(en)
|
2013-11-05 |
2022-02-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11207281B2
(en)
|
2013-11-05 |
2021-12-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9402843B2
(en)
|
2013-11-05 |
2016-08-02 |
Antecip Bioventures Ii Llc |
Compositions and methods of using threohydroxybupropion for therapeutic purposes
|
US10966974B2
(en)
|
2013-11-05 |
2021-04-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10940124B2
(en)
|
2019-01-07 |
2021-03-09 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10786469B2
(en)
|
2013-11-05 |
2020-09-29 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11969421B2
(en)
|
2013-11-05 |
2024-04-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US20200338022A1
(en)
|
2019-01-07 |
2020-10-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11541021B2
(en)
|
2013-11-05 |
2023-01-03 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11524007B2
(en)
|
2013-11-05 |
2022-12-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11285118B2
(en)
|
2013-11-05 |
2022-03-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11273134B2
(en)
|
2013-11-05 |
2022-03-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10105327B2
(en)
|
2013-11-05 |
2018-10-23 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
|
US11291638B2
(en)
|
2013-11-05 |
2022-04-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11576877B2
(en)
|
2013-11-05 |
2023-02-14 |
Antecip Bioventures Ii Llc |
Bupropion as modulator of drug activity
|
WO2015095713A1
(en)
|
2013-12-20 |
2015-06-25 |
Deuterx, Llc |
Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
|
CN106699527A
(zh)
*
|
2016-12-07 |
2017-05-24 |
三峡大学 |
一种间氯苯丙酮的合成方法
|
US10925842B2
(en)
|
2019-01-07 |
2021-02-23 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11717518B1
(en)
|
2022-06-30 |
2023-08-08 |
Antecip Bioventures Ii Llc |
Bupropion dosage forms with reduced food and alcohol dosing effects
|
US11730706B1
(en)
|
2022-07-07 |
2023-08-22 |
Antecip Bioventures Ii Llc |
Treatment of depression in certain patient populations
|